AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32820002 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP + PbtO2 group
Number of subjects: 300
Study 32820002 — intervention group
Group type: COMPARATOR
Intervention: ICP group
Number of subjects: 300
Study 35863457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole (600 mg on day 1 and 450 mg on day 2)
Number of subjects: 219
Study 35863457 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (3 sequential 150-mg doses every 72 hours)
Number of subjects: 219
Study 35863457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole (150 mg weekly for 11 weeks)
Number of subjects: 219
Study 35863457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mg weekly for 11 weeks)
Number of subjects: 219
Study 35863457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole (induction and maintenance phases)
Number of subjects: 219
Study 35863457 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (induction phase) and Placebo (maintenance phase)
Number of subjects: 219
Study 35863457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole
Number of subjects: 219
Study 35863457 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole and Placebo
Number of subjects: 219
Study 34298148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 190
Study 34298148 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 190
Study 33245788 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program (12 classes supervised by the Ministry of Health)
Number of subjects: 5208
Study 33245788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5208
Study 33028408 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing the nail plate after nail bed repair
Number of subjects: 0
Study 33028408 — intervention group
Group type: COMPARATOR
Intervention: Discarding the nail plate after nail bed repair
Number of subjects: 0
Study 33028408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Replacing and Discarding)
Number of subjects: 0
Study 35193441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of adalimumab
Number of subjects: 118
Study 35193441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for adalimumab
Number of subjects: 118
Study 35193441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of ustekinumab
Number of subjects: 118
Study 35193441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for ustekinumab
Number of subjects: 118
Study 35193441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of etanercept
Number of subjects: 118
Study 35193441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for etanercept
Number of subjects: 118
Study 32965727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 101
Study 32965727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot Water Immersion (HWI)
Number of subjects: 101
Study 32965727 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Ischemic Occlusion
Number of subjects: 101
Study 32965727 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Ischemic Occlusion
Number of subjects: 101
Study 32965727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pack Application
Number of subjects: 101
Study 32812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated exchange transfusion
Number of subjects: 83
Study 32812667 — intervention group
Group type: COMPARATOR
Intervention: Manual exchange transfusion
Number of subjects: 83
Study 32812667 — intervention group
Group type: COMPARATOR
Intervention: Simple transfusion
Number of subjects: 83
Study 35945733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA), administered once a week for 6 weeks (total of 6 sessions) on 14 defined knee areas.
Number of subjects: 40
Study 35945733 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, administered twice a week for 6 weeks (total of 12 sessions) on 9 defined acupuncture points.
Number of subjects: 40
Study 33230077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) bi-weekly for 6 weeks
Number of subjects: 8
Study 32482147 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work rate cycle ergometry (CWRCE)
Number of subjects: 151
Study 32482147 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance shuttle walking test (ESWT)
Number of subjects: 151
Study 32482147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 35238476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous ornithine phenylacetate (OP) at doses of 10, 15, or 20 g/day based on Child–Turcotte–Pugh score
Number of subjects: 0
Study 35238476 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 35238476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous ornithine phenylacetate (OP)
Number of subjects: 0
Study 36418494 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound as visual biofeedback
Number of subjects: 24
Study 36418494 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (verbal instruction, verbal reinforcement, and tactile cueing)
Number of subjects: 24
Study 33818978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injection (more effective)
Number of subjects: 750
Study 33818978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injection with decoy
Number of subjects: 750
Study 33818978 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-three-month injection with decoy
Number of subjects: 750
Study 32600400 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic treatment (IPDT)
Number of subjects: 270
Study 32600400 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 270
Study 32600400 — intervention group
Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 270
Study 32600400 — intervention group
Group type: COMPARATOR
Intervention: ICBT
Number of subjects: 270
Study 32600400 — intervention group
Group type: EXPERIMENTAL
Intervention: IPDT and ICBT
Number of subjects: 270
Study 36058694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated state
Number of subjects: 21
Study 33999960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages (SSB, 248 kcal, 20 fluid ounces)
Number of subjects: 20
Study 33999960 — intervention group
Group type: COMPARATOR
Intervention: Sugar sweetened solids (SSS, equivalent caloric intake to SSB)
Number of subjects: 20
Study 33999960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages (SSB)
Number of subjects: 20
Study 33999960 — intervention group
Group type: COMPARATOR
Intervention: Sugar sweetened solids (SSS)
Number of subjects: 20
Study 33999960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SSB and SSS
Number of subjects: 20
Study 32589455 — intervention group
Group type: EXPERIMENTAL
Intervention: VR game environment
Number of subjects: 25
Study 32589455 — intervention group
Group type: COMPARATOR
Intervention: Immersive desktop game environment
Number of subjects: 25
Study 33609762 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing alone
Number of subjects: 64
Study 33609762 — intervention group
Group type: COMPARATOR
Intervention: Compression dressing followed by sandbag compression
Number of subjects: 64
Study 36434888 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 134
Study 36434888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 32918131 — intervention group
Group type: COMPARATOR
Intervention: Ranking‐UP (WEAK) group
Number of subjects: 15
Study 35119462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard FIT mailed outreach plus an automated primer message through the electronic patient portal (intervention group)
Number of subjects: 2339
Study 35119462 — intervention group
Group type: COMPARATOR
Intervention: Standard FIT mailed outreach (control group)
Number of subjects: 2339
Study 34545652 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release dinoprostone vaginal delivery system (PROPESS)
Number of subjects: 117
Study 34545652 — intervention group
Group type: COMPARATOR
Intervention: Metreurynter
Number of subjects: 117
Study 32561673 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (NMDAR antagonist)
Number of subjects: 0
Study 32561673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 50
Study 35667400 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerine
Number of subjects: 50
Study 33188584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% DCI
Number of subjects: 46
Study 33188584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% DCI
Number of subjects: 46
Study 33188584 — intervention group
Group type: COMPARATOR
Intervention: 1% DCI, 0.25% DCI, vehiculum without active agent
Number of subjects: 46
Study 34853086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 or 4 weeks)
Number of subjects: 230
Study 33058553 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol test formulation/sucrose coadministration
Number of subjects: 48
Study 33058553 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol reference formulation/sucrose coadministration
Number of subjects: 48
Study 33058553 — intervention group
Group type: COMPARATOR
Intervention: Sucrose administration alone
Number of subjects: 48
Study 34313598 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time remote auscultation using a Bluetooth-connected electronic stethoscope
Number of subjects: 20
Study 34313598 — intervention group
Group type: COMPARATOR
Intervention: Classical auscultation using a traditional stethoscope
Number of subjects: 20
Study 32867690 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction model (nomogram) including estimated glomerular filtration rate (eGFR), serum albumin (ALB), age, and use of intra-aortic balloon pump (IABP)
Number of subjects: 1272
Study 32867690 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction model (nomogram)
Number of subjects: 1272
Study 32867690 — intervention group
Group type: COMPARATOR
Intervention: Classic Mehran CA-AKI model
Number of subjects: 1272
Study 33091687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 89
Study 33091687 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 89
Study 35777008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716
Number of subjects: 101
Study 35777008 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (Control)
Number of subjects: 101
Study 34302323 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial photodynamic therapy (IPDT)
Number of subjects: 0
Study 34302323 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) treatment
Number of subjects: 0
Study 33037320 — intervention group
Group type: EXPERIMENTAL
Intervention: H4:IC31 (subunit vaccine containing Ag85B and TB10.4)
Number of subjects: 90
Study 33037320 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (live attenuated vaccine)
Number of subjects: 90
Study 33037320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg
Number of subjects: 421
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg
Number of subjects: 421
Study 35674488 — intervention group
Group type: COMPARATOR
Intervention: Exhalation delivery system–placebo
Number of subjects: 421
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg (prior ESS)
Number of subjects: 421
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg (prior ESS)
Number of subjects: 421
Study 35674488 — intervention group
Group type: COMPARATOR
Intervention: Exhalation delivery system–placebo (unoperated)
Number of subjects: 421
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg (unoperated)
Number of subjects: 421
Study 35674488 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg (unoperated)
Number of subjects: 421
Study 34418958 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving the results of a SARS-CoV-2 antibody test
Number of subjects: 0
Study 34418958 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCap features for conducting RCT
Number of subjects: 0
Study 33370007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caffeine (perceived)
Number of subjects: 9
Study 33370007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose caffeine (perceived)
Number of subjects: 9
Study 33370007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (perceived)
Number of subjects: 9
Study 33689730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6‐12 hours
Number of subjects: 5010
Study 33689730 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 5010
Study 33689730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 5010
Study 33172445 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin status (normal vs deficient) in relation to MTHFR 677TT genotype
Number of subjects: 6076
Study 33172445 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient riboflavin status with MTHFR 677TT genotype
Number of subjects: 6076
Study 33172445 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment in participants with TT genotype
Number of subjects: 6076
Study 35467271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ziprasidone plus sertraline (ZS group)
Number of subjects: 452
Study 35467271 — intervention group
Group type: COMPARATOR
Intervention: Usual dose of ziprasidone (control group)
Number of subjects: 452
Study 33426778 — intervention group
Group type: EXPERIMENTAL
Intervention: Easily digestible meal (starch + sugar-rich meal, SSR)
Number of subjects: 16
Study 33426778 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly digestible meal (protein + fat-rich, PFR)
Number of subjects: 16
Study 32099328 — intervention group
Group type: EXPERIMENTAL
Intervention: LZM003 (test drug)
Number of subjects: 48
Study 32099328 — intervention group
Group type: COMPARATOR
Intervention: Ovidrel® (reference drug)
Number of subjects: 48
Study 33814237 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic neck dissection (TND)
Number of subjects: 570
Study 33814237 — intervention group
Group type: COMPARATOR
Intervention: Elective neck dissection (END)
Number of subjects: 570
Study 33814237 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 570
Study 33814237 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 tumors (DOI>10 mm)
Number of subjects: 570
Study 32151645 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410
Number of subjects: 0
Study 32151645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35985168 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Breathe Thrive (EBT) program
Number of subjects: 168
Study 35985168 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control condition
Number of subjects: 168
Study 33831660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 149
Study 33831660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE)
Number of subjects: 149
Study 33831660 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills Training in Affective and Interpersonal Regulation followed by PE (STAIR + PE)
Number of subjects: 149
Study 33831660 — intervention group
Group type: COMPARATOR
Intervention: CPTSD
Number of subjects: 149
Study 33027155 — intervention group
Group type: EXPERIMENTAL
Intervention: Current PrEP use by HIV-negative partners
Number of subjects: 120
Study 33027155 — intervention group
Group type: EXPERIMENTAL
Intervention: Current ART use by HIV-positive partners
Number of subjects: 120
Study 33027155 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence and viral load
Number of subjects: 120
Study 36273216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 20% cream
Number of subjects: 48
Study 36273216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 10% cream
Number of subjects: 48
Study 36273216 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin 20% cream, Phenytoin 10% cream, Placebo cream
Number of subjects: 48
Study 34667404 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus conventional therapy
Number of subjects: 80
Study 34667404 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 80
Study 35659538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 44
Study 35659538 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study 32273563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR)
Number of subjects: 52
Study 32273563 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Visualisation (3DM)
Number of subjects: 52
Study 32273563 — intervention group
Group type: COMPARATOR
Intervention: Text-only
Number of subjects: 52
Study 36191093 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS device implantation
Number of subjects: 153
Study 33667417 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 1210
Study 33667417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1210
Study 33667417 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg
Number of subjects: 1210
Study 33837482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pai‐Neng‐Da Capsule (PNDC) 320 mg/d plus cyclosporine 5 mg/(kg·d) plus andriol 80 mg/d
Number of subjects: 79
Study 33837482 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine 5 mg/(kg·d) plus andriol 160 mg/d
Number of subjects: 79
Study 33837482 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA group
Number of subjects: 79
Study 33139710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg single oral dose)
Number of subjects: 28
Study 33139710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 33734725 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 65
Study 33734725 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting Adderall
Number of subjects: 65
Study 33734725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 33734725 — intervention group
Group type: COMPARATOR
Intervention: Expecting caffeine
Number of subjects: 65
Study 34341037 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine-medicated plaster (LMP)
Number of subjects: 0
Study 34341037 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 32111343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of psilocybin
Number of subjects: 23
Study 32111343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 35902234 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT+MT
Number of subjects: 408
Study 35902234 — intervention group
Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 408
Study 34128894 — intervention group
Group type: EXPERIMENTAL
Intervention: Body and breath regulation group (n=72)
Number of subjects: 144
Study 34128894 — intervention group
Group type: COMPARATOR
Intervention: Body regulation group (n=72)
Number of subjects: 144
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels (measured in nmol/L) during DCCT/EDIC
Number of subjects: 693
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only
Number of subjects: 693
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC follow-up, adjusted for age and mean HbA1c
Number of subjects: 693
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC follow-up, fully adjusted for other CVD risk factors
Number of subjects: 693
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only, minimally adjusted
Number of subjects: 693
Study 32826295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only, fully adjusted
Number of subjects: 693
Study 33980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude journal intervention (logging 5 things they felt grateful for daily for 2 weeks)
Number of subjects: 84
Study 33980290 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily self-evaluations only)
Number of subjects: 84
Study 36008918 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF intervention
Number of subjects: 348
Study 36008918 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 348
Study 33909357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaodu Jieyu acupuncture combined with sertraline hydrochloride (50 mg once daily)
Number of subjects: 120
Study 33909357 — intervention group
Group type: COMPARATOR
Intervention: Sertraline hydrochloride (50 mg once daily)
Number of subjects: 120
Study 35228753 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of canagliflozin
Number of subjects: 476
Study 35228753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study 32649961 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 30
Study 32649961 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 30
Study 35302909 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS
Number of subjects: 5054
Study 35302909 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS+SDMT
Number of subjects: 5054
Study 35302909 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 5054
Study 35453106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stabilization
Number of subjects: 293